Abstract:Laryngeal mask airway surfactant administration (S‐LMA) has the potential benefit of surfactant administration whilst avoiding endotracheal intubation and ventilation, ventilator‐induced lung injury and bronchopulmonary dysplasia (BPD). To evaluate the benefits and harms of S‐LMA either as prophylaxis or treatment (rescue) compared to placebo, no treatment, or intratracheal surfactant administration via an endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) or extubate at standard criteria (S‐ETT) or via other less‐invasive surfactant administration (LISA) methods on morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome (RDS). We searched CENTRAL, MEDLINE, Embase, CINAHL, and three trial registries in December 2022. Randomised controlled trials (RCTs), cluster‐ or quasi‐RCTs of S‐LMA compared to placebo, no treatment, or other routes of administration (nebulised, pharyngeal instillation of surfactant before the first breath, thin endotracheal catheter surfactant administration or intratracheal surfactant instillation) on morbidity and mortality in preterm infants at risk of RDS. We considered published, unpublished and ongoing trials. Two review authors independently assessed studies for inclusion and extracted data. We used GRADE to assess the certainty of the evidence. We included eight trials (seven new to this update) recruiting 510 newborns. Five trials (333 infants) compared S‐LMA with surfactant administration via ETT with InSurE. One trial (48 infants) compared S‐LMA with surfactant administration via ETT with S‐ETT, and two trials (129 infants) compared S‐LMA with no surfactant administration. We found no studies comparing S‐LMA with LISA techniques or prophylactic or early S‐LMA. S‐LMA versus surfactant administration via InSurE S‐LMA may have little or no effect on the composite outcome of death or BPD at 36 weeks' postmenstrual age (risk ratio (RR) 1.50, 95% confidence interval (CI) 0.27 to 8.34, I 2 = not applicable (NA) as 1 study had 0 events; risk difference (RD) 0.02, 95% CI −0.07 to 0.10; I 2 = 0%; 2 studies, 110 infants; low‐certainty evidence). There may be a reduction in the need for mechanical ventilation at any time (RR 0.53, 95% CI 0.36 to 0.78; I 2 = 27%; RD −0.14, 95% CI −0.22 to −0.06, I 2 = 89%; number needed to treat for an additional beneficial outcome (NNTB) 7, 95% CI 5 to 17; 5 studies, 333 infants; low‐certainty evidence). However, this was limited to four studies (236 infants) using analgesia or sedation for the InSurE group. There was little or no difference for air leak during first hospitalisation (RR 1.39, 95% CI 0.65 to 2.98; I 2 = 0%; 5 studies, 333 infants (based on 3 studies as 2 studies had 0 events); low‐certainty evidence); BPD among survivors to 36 weeks' PMA (RR 1.28, 95% CI 0.47 to 3.52; I 2 = 0%; 4 studies, 264 infants (based on 3 studies as 1 study had 0 events); low‐certainty evidence); or death (all causes) during the first hospitalisation (RR 0.28, 95% CI 0.01 to 6.60; I 2 = NA as 2 studies had 0 events; 3 studies, 203 infants; low‐certainty evidence). Neurosensory disability was not reported. Intraventricular haemorrhage ( IVH) grades III and IV were reported among the study groups (1 study, 50 infants). S‐LMA versus surfactant administration via S‐ETT No study reported death or BPD at 36 weeks' PMA. S‐LMA may reduce the use of mechanical ventilation at any time compared with S‐ETT (RR 0.47, 95% CI 0.31 to 0.71; RD −0.54, 95% CI −0.74 to −0.34; NNTB 2, 95% CI 2 to 3; 1 study, 48 infants; low‐certainty evidence). We are very uncertain whether S‐LMA compared with S‐ETT reduces air leak during first hospitalisation (RR 2.56, 95% CI 0.11 to 59.75), IVH grade III or IV (RR 2.56, 95% CI 0.11 to 59.75) and death (all causes) during the first hospitalisation (RR 0.17, 95% CI 0.01 to 3.37) (1 study, 48 infants; very low‐certainty evidence). No study reported BPD to 36 weeks' PMA or neurosensory disability. S‐LMA versus no surfactant administration Rescue surfactant could be used in both groups. There may be little or no difference in death or BPD at 36 weeks (RR 1.65, 95% CI 0.85 to 3.22; I 2 = 58%; RD 0.08, 95% CI −0.03 to 0.19; I 2 = 0%; 2 studies, 129 infants; low‐certainty evidence). There was probably a reduction in the need for mechanical ventilation at any time with S‐LMA compared with nasal continuous positive airway pressure without surfactant (RR 0.57, 95% CI 0.38 to 0.85; I 2 = 0%; RD −0.24, 95% CI −0.40 to −0.08; I 2 = 0%; NNTB 4, 95% CI 3 to 13; 2 studies, 129 infants; moderate‐certainty evidence). There was little or no difference in air leak during first hospitalisation (RR 0.65, 95% CI 0.23 to 1.88; I 2 = 0%; 2 studies, 129 infants; low‐certainty evidence) or BPD to 36 weeks' -Abstract Truncated-

Feasibility and safety of surfactant administration via laryngeal mask airway as first-line therapy for a select newborn population: results of a standardized clinical protocol

Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Efficacy of Ultrasound for Placement of Laryngeal Mask Airway in Adult Patients: a Comparison with Fiberoptic Bronchoscopy

Laryngeal Mask for Minimally-Invasive Surfactant Administration: A Narrative Review

Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome

A Prospective Evaluation of the Efficacy of the Laryngeal Mask Airway During Neonatal Resuscitation

Prospective, Non-Blinded, Randomized Controlled Trial on Early Administration of Pulmonary Surfactant Guided by Lung Ultrasound Scores in Very Preterm Infants: Study Protocol

Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure

Substantiating and Adopting Lung Ultrasound Scores to Predict Surfactant Need in Preterm Neonates with Respiratory Distress Syndrome within an Institution

Lung Ultrasound Score for Prediction of Surfactant Administration in Preterm Infants with Respiratory Failure

Aerosolized surfactants

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model

Less invasive surfactant administration methods: Who, what and how

Less invasive surfactant administration (LISA): chances and limitations

Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial

Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits.

Comparing the Effects of Two Surfactant Administration Methods: Minimally Invasive Surfactant Therapy (MIST) with Intubation (INSURE) in Infants with Respiratory Distress Syndrome

Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis

Catheter and Laryngeal Mask Endotracheal Surfactant Therapy: the CALMEST approach as a novel MIST technique

Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits